April 3, 2017
The Ministry of Health, Labor and Welfare (MHLW) issued optimal promotion guidelines for the PCSK9 inhibitors Repatha (evolocumab) and Praluent (alirocumab) along with a “point-to-note” notification letter for health coverage on March 31. Optimal use guidelines are compiled for high-price...read more